October 11, 2024
Sanofi’s Frexalimab Shows Promise in Multiple Sclerosis with Positive Phase 2 Results
Sanofi, Frexalimab, Multiple Sclerosis, Phase 2 Trial, CD40L Antibody
Teva Pharmaceuticals Agrees to $450M Settlement Over Kickback and Price-Fixing Allegations
Teva Pharmaceuticals, False Claims Act, Anti-Kickback Statute, price-fixing, kickbacks, settlement, generic drugs, Medicare, Copaxone
Upstream Bio Expands IPO to $255 Million, Set to Join Nasdaq Alongside CAMP4
Upstream Bio, IPO, Nasdaq, CAMP4, Biotechnology, Inflammatory Diseases, Allergic Diseases
Gritstone Bio Files for Chapter 11 Bankruptcy, Casting Uncertainty Over Cancer Vaccine Development
Gritstone Bio, Chapter 11 bankruptcy, cancer vaccine, financial restructuring, clinical trials, immunotherapy, vaccine development.
Eli Lilly Rekindles Partnership with KeyBioscience to Bolster Obesity Drug Pipeline
Eli Lilly, obesity drugs, KeyBioscience, partnerships, weight loss treatments
Immatics Advances Melanoma T-Cell Therapy into Late-Stage Clinical Trials
Immatics, melanoma, T-cell therapy, ACTengine IMA203, late-stage clinical trials, SUPRAME Phase 3 trial
FDA Approves Roche’s Itovebi, a PI3K Inhibitor for Advanced Breast Cancer Treatment
Roche, Itovebi, PI3K inhibitor, breast cancer, FDA approval, PIK3CA mutation, hormone receptor-positive, HER2-negative
Glooko Secures $100 Million Funding to Enhance Diabetes Management Platform Under New Leadership
Glooko, diabetes management, healthcare technology, funding, new leadership
Ono Pharmaceutical Partners with LigaChem Biosciences for ADC Research and Development
Ono Pharmaceutical, LigaChem Biosciences, Antibody-Drug Conjugate (ADC), LCB97, ConjuAll ADC platform, Solid Tumors, Cancer Treatment
CMS Unveils Preliminary List of 101 Generic Drugs for Medicare $2 Out-of-Pocket Plan
Medicare $2 Drug List Model, generic drugs, out-of-pocket costs, medication adherence, health outcomes, CMS Innovation Center